Key Highlights
- FDA grants approval for Eli Lilly’s daily oral weight-loss medication orforglipron, marketed under the name Foundayo
- Commercial availability begins April 6 through LillyDirect platform priced at $149 monthly for direct-pay consumers
- Wall Street analysts forecast 2026 revenue between $1.5B (Guggenheim’s estimate) and $2.8B (Citi’s projection), with long-term peak sales potentially surpassing $40B
- Company has stockpiled $1.5B in inventory ahead of launch to prevent the supply shortages experienced with injectable medications
- Consensus analyst price target stands at $1,221, with majority of analysts maintaining Buy or Moderate Buy recommendations
Eli Lilly has achieved a significant regulatory milestone with its oral GLP-1 medication. The FDA’s green light for orforglipron — marketed as Foundayo — represents the pharmaceutical giant’s inaugural daily pill for weight management and positions it as a formidable competitor to Novo Nordisk’s market leadership.
Study participants taking Foundayo demonstrated weight reduction ranging from 12% to 15% of their total body weight. The medication works by targeting the GLP-1 hormone pathway, identical to the mechanism employed by Novo’s Ozempic and Wegovy injection therapies.
Commercial distribution of Foundayo launches April 6 exclusively through the LillyDirect platform. Patients paying out-of-pocket can obtain the entry-level dosage for $149 monthly — matching Ozempic’s price point.
Chief Executive David Ricks announced that regulatory filings for Foundayo have been submitted across more than 40 nations, indicating the company’s aggressive global expansion strategy is already underway.
The Street’s response has been notably positive. Financial analysts are estimating 2026 revenues spanning $1.5 billion to $2.8 billion, with Citi leading the optimistic outlook at $2.8B and suggesting ultimate annual sales could exceed $40 billion. J.P. Morgan’s forecast anticipates $6 billion in sales by 2027.
Bernstein adopted a somewhat reserved short-term perspective, noting that complimentary sampling programs, conservative initial dosing protocols, and pricing pressures might suppress early revenue performance despite potentially strong prescription growth. Weekly new patient initiations will serve as the critical metric for market observers.
Foundayo also benefits from production advantages. Manufacturing the oral formulation proves simpler than producing injectable GLP-1 medications, potentially enabling Lilly to expand capacity more rapidly — especially in global markets where injectable supply has been constrained.
Inventory Strategy After Previous Shortages
Lilly reports accumulating $1.5 billion in pre-launch stockpiles, a strategic response to availability problems that affected its injectable medications Zepbound and Mounjaro. Those supply gaps created opportunities for compounding pharmacies throughout the U.S. to market alternative versions. Lilly has subsequently initiated litigation against compounding facilities and wellness clinics distributing products purporting to contain tirzepatide.
Novo Nordisk continues competing aggressively. The Copenhagen-based pharmaceutical company has introduced subscription pricing models and product refinements in response. UBS analysts estimate the combined oral product offerings from both companies could generate approximately $5 billion during 2026, indicating rapid category expansion within obesity therapeutics.
Morningstar analysis suggests oral obesity medications might represent approximately one-third of a $180 billion worldwide market by 2034.
M&A Activity and Wall Street Sentiment
Lilly is simultaneously pursuing the acquisition of Centessa Pharmaceuticals through a transaction initially valued near $6.3 billion, extending its portfolio into sleep-wake disorder treatments and narcolepsy therapeutics. A legal firm has initiated an investor investigation regarding the Centessa transaction process, potentially creating complications before deal completion.
Regarding institutional activity, Westend Capital Management established a fresh LLY position during Q4, acquiring 16,393 shares valued at approximately $17.6 million. LLY currently represents roughly 4.9% of Westend’s total holdings.
Lilly delivered Q4 earnings per share of $7.54, exceeding analyst expectations of $7.48, with quarterly revenue reaching $19.29 billion compared to consensus estimates of $17.85 billion. Revenue climbed 42.6% year-over-year. Management established fiscal 2026 EPS guidance in the $33.50–$35.00 range.
Among 30 analysts tracking the stock, 23 assign Buy ratings, four recommend Hold, and one rates it Sell. The consensus price target stands at $1,221.26.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
